# **Anti-EBV Latent Membrane Protein 1 [CS 1-4]**

Catalogue number: 151471 Sub-type: Primary antibody

Images:

#### Contributor

**Inventor:** Martin Rowe

**Institute:** University of Birmingham

Images:

### **Tool details**

#### \*FOR RESEARCH USE ONLY

Name: Anti-EBV Latent Membrane Protein 1 [CS 1-4]

Alternate name:

Class: Monoclonal
Conjugate: Unconjugated

**Description:** Anti-EBV (CS1) is a latent membrane protein 1 antibody, which detects a specific epitope

upon LMP fusion protein in B-cell transformations, following EBV infection.

Purpose: Parental cell: Organism: Tissue: Model: Gender:

Isotype: IgG1 kappa Reactivity: Virus Selectivity:

Host: Mouse Immunogen: P03230

Immunogen UNIPROT ID: P03230

Sequence:

**Growth properties:** Production details:

Formulation:

Recommended controls: EBV transformed lymphoblastoid cell lines

Bacterial resistance: Selectable markers:

#### Additional notes:

# **Target details**

**Target:** Epstein-Barr Virus, Latent Membrane Protein 1 (EBV-LMP1)

#### **Target alternate names:**

Target background: A combination of four pooled antibodies which collectively detect the latent membrane protein (LMP) of EBV, an important effector protein in B-cell transformation under EBV infection, across 20 geographically distinct EBV isolates. EBV is a human herpesvirus that establishes a life-long persistence in the host. The virus infects the vast majority of the world's adult population and is well known for its association with a broad spectrum of benign and malignant diseases. These include infectious mononucleosis, Burkitt's lymphoma, nasopharyngeal carcinoma, and is causally associated with lymphoid and epithelial malignancies, including post-transplant lymphoproliferative disorders, Hodgkin's disease, anaplastic nasopharyngeal carcinoma and gastric carcinomas. Latent membrane protein 1 (LMP1) of Epstein-Barr virus (EBV) is a transforming protein that affects multiple cell signalling pathways and contributes to EBV-associated oncogenesis. LMP1 can be expressed in some states of EBV latency, and significant induction of full-length LMP1 is also observed frequently during virus reactivation into the lytic cycle. LMP1 is critical for EBV-infected cell activation, adhesion and survival, and is usually expressed in the malignant cells. These antibodies were created to examine various aspects of LMP expression in B-cell lines transformed in vitro, detecting LMPs from 20 geographically varied EBV isolates.

Molecular weight: 57-66 kDa

Ic50:

## **Applications**

Application: IHC; IHC; IF; IP; WB

**Application notes:** 

# **Handling**

Format: Liquid

Concentration: 1 mg/ml

Passage number: Growth medium: Temperature: Atmosphere: Volume:

Storage medium:

Storage buffer: PBS with 0.02% azide

Storage conditions: Store at -20° C frozen. Avoid repeated freeze / thaw cycles

**Shipping conditions:** 

Shipping at 4° C

### Related tools

Related tools: Anti-EBV Latent Membrane Protein 1 [LMPO24]

### References

**References:** Morgenstern et al. 1990. Nucleic Acids Res. 18(12):3587-96. PMID: 2194165. ; Advanced mammalian gene transfer: high titre retroviral vectors with multiple drug selection markers and a complementary helper-free packaging cell line.

